BidaskClub upgraded shares of Cutera, Inc. (NASDAQ:CUTR) from a buy rating to a strong-buy rating in a report released on Wednesday.
A number of other equities research analysts also recently weighed in on the company. Zacks Investment Research downgraded Cutera from a hold rating to a sell rating in a research report on Thursday, May 4th. TheStreet downgraded Cutera from a b- rating to a c rating in a research report on Monday, May 1st. Sidoti restated a buy rating and issued a $30.00 target price (up from $27.00) on shares of Cutera in a research report on Saturday, June 3rd. Finally, Roth Capital started coverage on Cutera in a research report on Monday, June 26th. They issued a buy rating and a $32.00 target price for the company. Four analysts have rated the stock with a buy rating and one has given a strong buy rating to the company’s stock. Cutera has a consensus rating of Buy and a consensus price target of $31.50.
Cutera (CUTR) opened at 27.00 on Wednesday. Cutera has a one year low of $10.43 and a one year high of $29.25. The company’s 50-day moving average price is $23.01 and its 200 day moving average price is $20.36. The firm has a market capitalization of $374.17 million, a PE ratio of 103.45 and a beta of 0.60.
Cutera (NASDAQ:CUTR) last released its earnings results on Monday, May 1st. The medical device company reported ($0.07) earnings per share for the quarter, hitting analysts’ consensus estimates of ($0.07). The firm had revenue of $29.30 million during the quarter, compared to the consensus estimate of $29 million. Cutera had a return on equity of 9.21% and a net margin of 2.89%. The firm’s revenue for the quarter was up 30.8% compared to the same quarter last year. During the same period in the prior year, the firm posted ($0.16) earnings per share. On average, analysts forecast that Cutera will post $0.46 earnings per share for the current year.
In other news, EVP Larry Laber sold 1,000 shares of the stock in a transaction on Wednesday, June 28th. The stock was sold at an average price of $25.88, for a total transaction of $25,880.00. Following the completion of the sale, the executive vice president now owns 73,140 shares in the company, valued at approximately $1,892,863.20. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director David A. Gollnick sold 10,000 shares of the stock in a transaction on Monday, June 26th. The shares were sold at an average price of $25.08, for a total value of $250,800.00. Following the sale, the director now owns 26,641 shares of the company’s stock, valued at approximately $668,156.28. The disclosure for this sale can be found here. Insiders have sold a total of 160,410 shares of company stock valued at $3,410,284 in the last quarter. Insiders own 3.30% of the company’s stock.
Several large investors have recently made changes to their positions in the stock. Federated Investors Inc. PA increased its stake in shares of Cutera by 143.7% in the fourth quarter. Federated Investors Inc. PA now owns 12,568 shares of the medical device company’s stock worth $218,000 after buying an additional 7,410 shares during the period. Icon Advisers Inc. Co. bought a new stake in shares of Cutera during the first quarter worth approximately $571,000. Two Sigma Investments LP increased its stake in shares of Cutera by 16.4% in the fourth quarter. Two Sigma Investments LP now owns 53,498 shares of the medical device company’s stock worth $928,000 after buying an additional 7,519 shares during the period. Russell Investments Group Ltd. bought a new stake in shares of Cutera during the fourth quarter worth approximately $321,000. Finally, Oxford Asset Management increased its stake in shares of Cutera by 98.4% in the first quarter. Oxford Asset Management now owns 52,100 shares of the medical device company’s stock worth $1,078,000 after buying an additional 25,839 shares during the period. Institutional investors own 81.42% of the company’s stock.
Cutera, Inc is a medical device company. The Company is engaged in the design, development, manufacture, marketing and servicing of laser and other energy-based aesthetics systems for practitioners across the world. The Company offers products based on product platforms, such as enlighten, excel HR, truSculpt, excel V and xeo, each of which enables physicians and other practitioners to perform aesthetic procedures for customers.
Receive News & Ratings for Cutera Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cutera Inc. and related companies with MarketBeat.com's FREE daily email newsletter.